PU H71

Drug Profile

PU H71

Alternative Names: PU-H71; Purine-scaffold HSP90 inhibitor - Samus

Latest Information Update: 10 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Samus Therapeutics
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelofibrosis
  • Phase I Breast cancer; Lymphoma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 23 May 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03166085)
  • 30 Mar 2017 Samus Therapeutics plans a phase Ib trial for Breast cancer (Combination therapy, First-line therapy, Metastatic disease)
  • 30 Mar 2017 Phase-I clinical trials in Breast cancer (Late-stage disease, Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top